C-Path Awards Research Grant to Christopher Hulme, PhD
Grant will advance novel compounds through the drug development process.
The Critical Path Institute's Translational Therapeutics Accelerator (TRxA) awarded a research grant to Christopher Hulme, PhD to advance novel compounds through the drug development process.
Dr. Hulme is a professor of medicinal chemistry and co-director of the Arizona Center for Drug Discovery within the department of pharmacology and toxicology within the College of Pharmacy. He is joined by William Montfort, PhD, a professor in the department of chemistry and biochemistry in the UArizona College of Science and Sourav Banerjee, PhD, an assistant professor from the School of Medicine at the University of Dundee.
Their focus is to establish a pleiotropic brain-penetrant small-molecule to impede glioblastoma (GBM), a rare and highly invasive form of brain cancer. The team received $250,000 to proceed with their research. If drug discovery deliverables are met, the team will receive additional funding to advance their work.
Launched in 2022, TRxA is a global drug discovery and development program focused on supporting academic scientists in defining optimal strategies for advancing new, cutting-edge therapeutics, from the lab to patients.